| Bioactivity | TLR7/8 agonist 9 (Compound 25a) is a TLR7/8 agonist, with EC50s of 40 nM and 23 nM for hTLR7/8. TLR7/8 agonist 9 has anti-tumor activity and improves the antitumor activity of PD-1/PD-L1 blockade. TLR7/8 agonist 9 can be used for research of cancer immunotherapy[1]. |
| Target | EC50s: 40 nM and 23 nM for hTLR7/8 |
| Name | TLR7/8 agonist 9 |
| CAS | 2649170-17-0 |
| Formula | C20H26N6O |
| Molar Mass | 366.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang Z, et al. Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy. J Med Chem. 2021 Jun 10;64(11):7507-7532. |
TLR7/8 agonist 9
CAS: 2649170-17-0 F: C20H26N6O W: 366.46
TLR7/8 agonist 9 (Compound 25a) is a TLR7/8 agonist, with EC50s of 40 nM and 23 nM for hTLR7/8. TLR7/8 agonist 9 has ant
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.